The evolutionary puzzle of Escherichia coli ST131.


Journal

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
ISSN: 1567-7257
Titre abrégé: Infect Genet Evol
Pays: Netherlands
ID NLM: 101084138

Informations de publication

Date de publication:
07 2020
Historique:
received: 09 12 2019
revised: 22 02 2020
accepted: 26 02 2020
pubmed: 1 3 2020
medline: 29 6 2021
entrez: 1 3 2020
Statut: ppublish

Résumé

The abrupt expansion of Escherichia coli sequence type (ST) 131 is unmatched among Gram negative bacteria. In many ways, ST131 can be considered a real-world model for the complexities involved in the evolution of a multidrug resistant pathogen. While much progress has been made on our insights into the organism's population structure, pathogenicity and drug resistance profile, significant gaps in our knowledge remain. Whole genome studies have shed light on key mutations and genes that have been selected against the background of antibiotics, but in most cases such events are inferred and not supported by experimental data. Notable examples include the unknown fitness contribution made by specific plasmids, genomic islands and compensatory mutations. Furthermore, questions remain like why this organism in particular achieved such considerable success in such a short time span, compared to other more pathogenic and resistant clones. Herein, we document what is known regarding the genetics of this organism since its first description in 2008, but also highlight where work remains to be done for a truly comprehensive understanding of the biology of ST131, in order to account for its dramatic rise to prominence.

Identifiants

pubmed: 32112974
pii: S1567-1348(20)30096-4
doi: 10.1016/j.meegid.2020.104265
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104265

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest JP and TF have no conflicts of interest relevant to the content of this article.

Auteurs

Johann D D Pitout (JDD)

Department of Pathology and Laboratory Medicine, Cummings School of Medicine, 3330 Hospital Dr NW, Calgary, Alberta T2N 4N1, Canada; Department of Medical Microbiology, University of Pretoria, Pretoria, Gauteng, South Africa; Division of Microbiology, Alberta Precision Laboratories, 3535 Research Rd NW, Calgary, Alberta T2L 2K8, Canada. Electronic address: johann.pitout@albertaprecisionlabs.ca.

Thomas J Finn (TJ)

Department of Microbiology, Immunology & Infectious Diseases, Cummings School of Medicine, 3330 Hospital Dr NW, Calgary, Alberta T2N 4N1, Canada. Electronic address: thomas.finn@ucalgary.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH